LayerBio

LayerBio is an ophthalmic drug delivery company pioneering a novel, bioerodible sustained-release technology called OcuRing™. The platform is engineered to integrate with any standard intraocular lens (IOL) implanted during cataract surgery, aiming to provide localized, long-term delivery of therapeutics to the anterior and posterior segments of the eye. This approach targets a significant unmet need for effective post-surgical management of inflammation and pain, and potentially chronic conditions like glaucoma or macular edema, without requiring additional injections or patient compliance. As a private, preclinical-stage entity, the company is positioned to capitalize on the massive and growing cataract surgery market by enhancing the standard-of-care procedure with a built-in therapeutic delivery mechanism.

OcuRing™: A bioerodible, ring-shaped polymer matrix for sustained intraocular drug delivery, designed to be implanted alongside a standard intraocular lens (IOL) during cataract surgery.

Competition includes established topical eye drop formulations (generic and branded) and other sustained-release technologies like intracameral injections (e.g., Dextenza®) or injectable implants (e.g., Ozurdex®). The most significant competitive threat may come from large IOL manufacturers (e.g., Alcon, Johnson & Johnson, Bausch + Lomb) who are actively developing their own drug-eluting IOLs or adjunctive devices, potentially creating barriers to market access for an independent platform like OcuRing™.